Effectiveness and safety of Ivermectin in COVID-19 patients: A prospective study at a safety-net hospital.
Adult
Aged
Aged, 80 and over
COVID-19
/ mortality
Female
Hospital Mortality
Humans
Intensive Care Units
Ivermectin
/ administration & dosage
Length of Stay
/ statistics & numerical data
Logistic Models
Male
Middle Aged
Propensity Score
Prospective Studies
Respiration, Artificial
Safety-net Providers
Young Adult
COVID-19 Drug Treatment
COVID-19
Ivermectin
efficacy
prospective study
safety profile
Journal
Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
revised:
15
11
2021
received:
26
08
2021
accepted:
19
11
2021
pubmed:
24
11
2021
medline:
5
3
2022
entrez:
23
11
2021
Statut:
ppublish
Résumé
Ivermectin has been found to inhibit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication in vitro. It is unknown whether this inhibition of SARS-CoV-2 replication correlates with improved clinical outcomes. To assess the effectiveness and safety of ivermectin in hospitalized patients with COVID-19. A total of 286 patients with COVID-19 were included in the study. Univariate analysis of the primary mortality outcome and comparisons between treatment groups were determined. Logistic regression and propensity score matching (PSM) was used to adjust for confounders. Patients in the ivermectin group received 2 doses of Ivermectin at 200 μg/kg in addition to usual clinical care on hospital Days 1 and 3. The ivermectin group had a significantly higher length of hospital stay than the control group; however, this significance did not maintain on multivariable logistic regression analysis. The length of intensive care unit (ICU) stay and duration of mechanical ventilation were longer in the control group. However, a mortality benefit was not seen with ivermectin treatment before and after PSM (p values = 0.07 and 0.11, respectively). ICU admission, and intubation rate were not significantly different between the groups (p = 0.49, and p = 1.0, respectively). No differences were found between groups regarding the length of hospital stay, ICU admission, intubation rate, and in-hospital mortality.
Identifiants
pubmed: 34811753
doi: 10.1002/jmv.27469
pmc: PMC9011757
doi:
Substances chimiques
Ivermectin
70288-86-7
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1473-1480Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Chest. 2021 Jan;159(1):85-92
pubmed: 33065103
Clin Infect Dis. 2018 Sep 28;67(8):1247-1255
pubmed: 29617737
Biochem J. 2012 May 1;443(3):851-6
pubmed: 22417684
Nat Rev Drug Discov. 2017 Aug;16(8):565-586
pubmed: 28473729
In Vivo. 2020 Sep-Oct;34(5):3023-3026
pubmed: 32871846
Antiviral Res. 2020 May;177:104760
pubmed: 32135219
J Med Virol. 2022 Apr;94(4):1473-1480
pubmed: 34811753
PLoS Negl Trop Dis. 2018 Jan 18;12(1):e0006020
pubmed: 29346388
Front Microbiol. 2021 Jan 25;11:592908
pubmed: 33746908
J Virol. 2005 Sep;79(17):11507-12
pubmed: 16103202
J Antimicrob Chemother. 2020 Apr 1;75(4):827-834
pubmed: 31960060
Int J Infect Dis. 2021 Feb;103:214-216
pubmed: 33278625
Antiviral Res. 2020 Jun;178:104787
pubmed: 32251768
PLoS One. 2020 Nov 11;15(11):e0242184
pubmed: 33175880
Virus Res. 2005 Dec;114(1-2):23-34
pubmed: 15992957
Trans R Soc Trop Med Hyg. 2004 Aug;98(8):496-504
pubmed: 15186939
Am J Ther. 2021 Apr 22;28(3):e299-e318
pubmed: 34375047
Clin Infect Dis. 2019 Sep 13;69(7):1112-1119
pubmed: 30590537